Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

USP1 Inhibitor ISM3091

An orally bioavailable small molecule inhibitor of the human deubiquitinating enzyme ubiquitin specific protease 1 (USP1), with potential antineoplastic activity. Upon oral administration, USP1 inhibitor ISM3091 specifically targets, binds to and inhibits the activity of USP1, thereby blocking USP1-mediated deubiquitinating activity. This may result in replication fork degradation, inhibition of DNA damage repair, and decreased tumor cell survival. USP1, a deubiquitinating enzyme overexpressed in various tumor cell types, plays a key role in the correct folding and deubiquitylation of proteins and facilitates DNA repair via its role regulating the Fanconi anemia complex and translesion synthesis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:ISM 3091
ISM-3091
ISM3091
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search